Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi Sells 864 Shares

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 864 shares of Phreesia stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total value of $20,571.84. Following the sale, the chief financial officer now owns 107,547 shares of the company’s stock, valued at approximately $2,560,694.07. This represents a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, April 8th, Balaji Gandhi sold 8,045 shares of Phreesia stock. The shares were sold at an average price of $23.85, for a total transaction of $191,873.25.
• On Wednesday, March 26th, Balaji Gandhi sold 1,827 shares of Phreesia stock. The stock was sold at an average price of $27.46, for a total transaction of $50,169.42.
• On Tuesday, February 18th, Balaji Gandhi sold 5,771 shares of Phreesia stock. The shares were sold at an average price of $30.04, for a total transaction of $173,360.84.
• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The stock was sold at an average price of $30.00, for a total transaction of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The shares were sold at an average price of $27.48, for a total value of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total value of $159,135.37.

Phreesia Stock Up 0.1 %

NYSE PHR opened at $23.92 on Friday. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $30.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The stock has a market cap of $1.41 billion, a PE ratio of -16.27 and a beta of 0.82. The firm has a 50-day simple moving average of $26.16 and a 200 day simple moving average of $24.28.

Institutional Trading of Phreesia

A number of hedge funds have recently modified their holdings of PHR. Johnson Financial Group Inc. increased its position in shares of Phreesia by 381.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after purchasing an additional 896 shares during the period. R Squared Ltd acquired a new stake in Phreesia during the fourth quarter worth $30,000. BankPlus Trust Department bought a new stake in Phreesia in the 4th quarter valued at $34,000. Quarry LP raised its stake in shares of Phreesia by 210.9% in the 4th quarter. Quarry LP now owns 2,835 shares of the company’s stock valued at $71,000 after buying an additional 1,923 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new position in shares of Phreesia during the 4th quarter worth about $76,000. Institutional investors own 92.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PHR. DA Davidson cut their price objective on Phreesia from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Monday. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Canaccord Genuity Group upped their price objective on shares of Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. KeyCorp dropped their target price on shares of Phreesia from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating and set a $33.00 target price (up previously from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia presently has an average rating of “Buy” and a consensus target price of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.